Semaglutide and Tirzepatide, FDA-approved for Medical Weight Loss, are weekly injections that have shown significant body weight reduction, 17% to 22% respectively. These GLP-1 receptor agonists trigger the pancreas to release insulin, utilizing stored sugars and promoting energy consumption for weight loss. Tirzepatide has an added function of releasing GIP, modulating glucagon which also aids in insulin release. These medications work by increasing insulin, reducing hunger, and slowing stomach emptying, making one feel fuller longer, thereby effectively facilitating weight loss